SABATO Trial: Oral Antibiotics for Staph Aureus

sabato trial

Here’s the extracted information from the provided visual abstract:


Efficacy and Safety of an Early Oral Switch in Low-risk Staphylococcus aureus Bloodstream Infection

Study Design:

  • An open-label, non-inferiority, randomized, controlled trial.


  • To assess the efficacy and safety of an early switch to oral therapy in patients at low risk for complications related to Staphylococcus aureus bloodstream infection, as compared to continuous intravenous antimicrobial therapy.


  • Total: 213 Patients
  • Inclusion Criteria:
    • Aged 18 or older
    • Blood culture positive for Staphylococcus aureus
    • 5-7 days of appropriate intravenous (IV) antimicrobial therapy
    • Absence of persistent bacteremia
  • Exclusion Criteria:
    • Complicated Staphylococcus aureus bloodstream infection
    • Non-removable foreign devices
    • Severe comorbidity

Intervention Groups:

  • Oral Switch Therapy (n = 108)
  • Intravenous Standard Therapy (n = 105)

Primary Outcome:

  • Occurrence of any complication related to Staphylococcus aureus bloodstream infection within 90 days
  • Results:
    • Oral Switch Therapy: 13%
    • Intravenous Standard Therapy: 12%
    • Difference: 0.7% (Confidence Interval: -7.8% to 9.1%; P = 0.013)

Secondary Outcome:

  • Adverse event in safety population
  • Results:
    • Oral Switch Therapy: 34%
    • Intravenous Standard Therapy: 26%
    • (P = 0.29)


  • Oral switch antimicrobial therapy was non-inferior to intravenous standard therapy in participants with low-risk Staphylococcus aureus bloodstream infection.


This summary captures the key points from the visual abstract, including study design, objectives, participant details, intervention groups, outcomes, and the conclusion.

Comments are closed.